Company intelligence / Profile preview
Paradigm Biopharmaceuticals
Melbourne, Victoria, Australiaparadigmbiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Paradigm's lead product Zilosul® (injectable pentosan polysulfate sodium/iPPS) has completed Phase 2 trials for osteoarthritis with positive results showing reductions in nerve growth factor (NGF) indicating pain reduction mechanisms. The company is currently conducting Phase 3 trials for knee osteoarthritis.
- Therapeutic areas
- ImmunologyRare DiseasesRheumatology
- Modalities
- Small moleculesPolymers
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
bene parmaChem (exclusive 25-year supply agreement)
Beyond the preview
Go deeper on Paradigm Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paradigm Biopharmaceuticals.